EP0669932A4 - Acyl-3-carboxy-3,5-dienes a substitution 17-alkyle et 17-beta et utilisation de ces derniers pour inhiber la 5-alpha-reductase. - Google Patents

Acyl-3-carboxy-3,5-dienes a substitution 17-alkyle et 17-beta et utilisation de ces derniers pour inhiber la 5-alpha-reductase.

Info

Publication number
EP0669932A4
EP0669932A4 EP94902307A EP94902307A EP0669932A4 EP 0669932 A4 EP0669932 A4 EP 0669932A4 EP 94902307 A EP94902307 A EP 94902307A EP 94902307 A EP94902307 A EP 94902307A EP 0669932 A4 EP0669932 A4 EP 0669932A4
Authority
EP
European Patent Office
Prior art keywords
alpha
dienes
reductase
carboxy
inhibiting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP94902307A
Other languages
German (de)
English (en)
Other versions
EP0669932A1 (fr
Inventor
Dennis Alan Holt
Mark Alan Levy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929224213A external-priority patent/GB9224213D0/en
Priority claimed from GB939316954A external-priority patent/GB9316954D0/en
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of EP0669932A1 publication Critical patent/EP0669932A1/fr
Publication of EP0669932A4 publication Critical patent/EP0669932A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0014—Androstane derivatives substituted in position 17 alfa, not substituted in position 17 beta
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C07J3/005—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom the carbon atom being part of a carboxylic function
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0066—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by a carbon atom forming part of an amide group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP94902307A 1992-11-18 1993-11-18 Acyl-3-carboxy-3,5-dienes a substitution 17-alkyle et 17-beta et utilisation de ces derniers pour inhiber la 5-alpha-reductase. Withdrawn EP0669932A4 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB929224213A GB9224213D0 (en) 1992-11-18 1992-11-18 Compounds
GB9224213 1992-11-18
GB9316954 1993-08-14
GB939316954A GB9316954D0 (en) 1993-08-14 1993-08-14 Compounds
PCT/US1993/011241 WO1994011386A1 (fr) 1992-11-18 1993-11-18 Acyl-3-carboxy-3,5-dienes a substitution 17-alkyle et 17-beta et utilisation de ces derniers pour inhiber la 5-alpha-reductase

Publications (2)

Publication Number Publication Date
EP0669932A1 EP0669932A1 (fr) 1995-09-06
EP0669932A4 true EP0669932A4 (fr) 1995-10-25

Family

ID=26302003

Family Applications (2)

Application Number Title Priority Date Filing Date
EP94901600A Withdrawn EP0673251A1 (fr) 1992-11-18 1993-11-18 Steroides 17 substitutes acyle-3-carboxy 3,5-diene en tant qu'inhibiteurs de 5-alpha-reductase
EP94902307A Withdrawn EP0669932A4 (fr) 1992-11-18 1993-11-18 Acyl-3-carboxy-3,5-dienes a substitution 17-alkyle et 17-beta et utilisation de ces derniers pour inhiber la 5-alpha-reductase.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP94901600A Withdrawn EP0673251A1 (fr) 1992-11-18 1993-11-18 Steroides 17 substitutes acyle-3-carboxy 3,5-diene en tant qu'inhibiteurs de 5-alpha-reductase

Country Status (12)

Country Link
EP (2) EP0673251A1 (fr)
JP (1) JPH08503471A (fr)
CN (2) CN1101914A (fr)
AP (1) AP9300589A0 (fr)
AU (2) AU5613394A (fr)
CA (1) CA2149427A1 (fr)
IL (1) IL107611A0 (fr)
MA (1) MA23036A1 (fr)
MX (1) MX9307203A (fr)
NZ (1) NZ258723A (fr)
SI (1) SI9300601A (fr)
WO (2) WO1994011004A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW369521B (en) * 1993-09-17 1999-09-11 Smithkline Beecham Corp Androstenone derivative
GB9415183D0 (en) * 1994-07-28 1994-09-21 Erba Carlo Spa 3-carboxysteroids with a fluorinated side-chain
GB9415178D0 (en) * 1994-07-28 1994-09-21 Erba Carlo Spa 4-azasteroids with side-chain fluoroketones
JPH10507176A (ja) * 1994-10-05 1998-07-14 スミスクライン・ビーチャム・コーポレイション １７−ベータ−置換アンドロスタ−３，５−ジエン−３−カルボン酸の製法
US5541322A (en) * 1994-10-14 1996-07-30 Glaxo Wellcome Inc. Synthesis of 6-azaandrostenones
US5543417A (en) * 1994-10-21 1996-08-06 Merck & Co., Inc. Combination method of treating acne using 4-AZA-5α-cholestan-ones and 4-AZA-5α-androstan-ones as selective 5α-reductase inhibitors with anti-bacterial, keratolytic, or anti-inflammatory agents
CA2309350C (fr) 1997-11-12 2007-04-03 Mitsubishi Chemical Corporation Derives de purine et medicament les renfermant en tant qu'ingredient actif
CN1160355C (zh) 1999-05-11 2004-08-04 三菱化学株式会社 嘌呤衍生物二水合物、含有该化合物作为有效成分的药物及其制备中间体
FR2817257B1 (fr) 2000-11-30 2009-03-20 Sanofi Synthelabo Cyclohexyl(alkyl)-propanolamines, leur preparation et compositions pharmaceutiques en contenant
GB201102913D0 (en) 2011-02-18 2011-04-06 Univ Birmingham Novel therapeutic

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0465123A2 (fr) * 1990-06-28 1992-01-08 Merck & Co. Inc. Nouveaux produits intermédiaires pour la production des 17-bêta-acyle-3-carboxy-androsta-3,5-diènes
EP0465142A1 (fr) * 1990-06-28 1992-01-08 Merck & Co. Inc. 17-Bêta-acyl-3-carboxy-androsta-3,5-diènes comme inhibiteurs de testostérone 5-alpha réductase

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5041433A (en) * 1987-04-29 1991-08-20 Smithkline Beecham Corporation 11-keto or hydroxy 3,5-diene steroids as inhibitors of steriod 5-α-reductase
US4910226A (en) * 1987-04-29 1990-03-20 Smithkline Beckman Corporation Steroid 5-alpha-reductase inhibitors
US4954446A (en) * 1988-05-25 1990-09-04 Smithkline Beecham Corporation Aromatic steroid 5-α-reductase inhibitors
US5032586A (en) * 1989-08-24 1991-07-16 Smithkline Beecham Corporation 7-keto or hydroxy 3,5-diene steroids as inhibitors of steroid 5-alpha reductase
US5137882A (en) * 1990-06-11 1992-08-11 Holt Dennis A Steroidal 3-acetic acid derivatives as 5-alpha-reductase inhibitors
US5091380A (en) * 1990-06-28 1992-02-25 Merck & Co., Inc. N-monosubstituted adamantyl/norbornanyl 17β-carbamides of 3-carboxy-androst-3,5-dienes as testosterone 5α-reductase inhibitors
US5196411A (en) * 1991-08-16 1993-03-23 Merck & Co., Inc. 17β-acyl-3-carboxy-androsta-3,5-dienes as testosterone 5α-reductase inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0465123A2 (fr) * 1990-06-28 1992-01-08 Merck & Co. Inc. Nouveaux produits intermédiaires pour la production des 17-bêta-acyle-3-carboxy-androsta-3,5-diènes
EP0465142A1 (fr) * 1990-06-28 1992-01-08 Merck & Co. Inc. 17-Bêta-acyl-3-carboxy-androsta-3,5-diènes comme inhibiteurs de testostérone 5-alpha réductase

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO9411386A1 *

Also Published As

Publication number Publication date
WO1994011004A1 (fr) 1994-05-26
CN1101914A (zh) 1995-04-26
AU5671794A (en) 1994-06-08
NZ258723A (en) 1996-12-20
MX9307203A (es) 1994-07-29
JPH08503471A (ja) 1996-04-16
AP9300589A0 (en) 1994-01-31
IL107611A0 (en) 1994-02-27
MA23036A1 (fr) 1994-07-01
CA2149427A1 (fr) 1994-05-26
EP0673251A4 (fr) 1995-10-25
SI9300601A (en) 1994-06-30
EP0669932A1 (fr) 1995-09-06
WO1994011386A1 (fr) 1994-05-26
CN1101916A (zh) 1995-04-26
AU5613394A (en) 1994-06-08
EP0673251A1 (fr) 1995-09-27

Similar Documents

Publication Publication Date Title
EP0630658A3 (fr) Hytérosalpingographie et salpingographie sélective.
ZA97860B (en) Skin smoothing compositions containing hydroxyacids and methods for using same.
EP0611168A3 (fr) Extrait de houblon et son utilisation.
ZA981132B (en) Methods, compositions and articles for reducing or preventing the effects of inflammation.
HU0500549D0 (en) Azolo-pyridimidines, pharmaceutical compositions containing the same and use thereof
EP0634131A3 (fr) Distributeur embrochable pour articles hygiéniques et similaires.
ZA978885B (en) Colostrinin and uses thereof.
ZA989695B (en) Nut, and device for tightening provided in the same.
PH31600A (en) Methods of inhibiting atrophy of the skin and vagina.
EP0596962A4 (en) Therapeutic compositions and methods.
IL104749A0 (en) Quinobenzoxazine,quinobenzothiazine,and pyrido-acridine antineoplastic agents
HUP9902449A3 (en) Androstene derivatives, medicaments containing the same and their use
IL120262A (en) Droloxifene and derivatives thereof for use in increasing serum testosterone levels
ZA93110B (en) Probiotic agent.
ZA979011B (en) Hormonal composition and its use.
ZA975288B (en) The use of TCET in the prophylaxis and treatment of allergies.
ZA988167B (en) Synergistic compositions comprising imazalil and epoxiconazole.
ZA988529B (en) Synergistic herbicidal methods and compositions.
GB9600661D0 (en) Bactericidal compostions and articles containing them
ZA9711047B (en) Formulation and use.
PL331283A1 (en) Preparation for treating and/or preventing stupefaction
IL116504A0 (en) 14, 17-C2-bridged steroids and pharmaceutical compositions containing the same
EP0940419A4 (fr) Copolymere aromatique et composition le contenant
GR3024722T3 (en) Copper-manganese-aluminium alloy and its use.
EP0592941A3 (fr) Composition de polyamide et utilisation.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19950516

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 19950908

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

RHK1 Main classification (correction)

Ipc: C07J 9/00

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19990601